{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rocco PRM"],"funding":["Conselho Nacional de Desenvolvimento Científico e Tecnológico"],"pagination":["2003725"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7758778"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["58(1)"],"pubmed_abstract":["<h4>Background</h4>Nitazoxanide is widely available and exerts broad-spectrum antiviral activity <i>in vitro</i>. However, there is no evidence of its impact on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.<h4>Methods</h4>In a multicentre, randomised, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of coronavirus disease 2019 (COVID-19) symptoms (dry cough, fever and/or fatigue) were enrolled. After confirmation of SARS-CoV-2 infection using reverse transcriptase PCR on a nasopharyngeal swab, patients were randomised 1:1 to receive either nitazoxanide (500 mg) or placebo, three times daily, for 5 days. The primary outcome was complete resolution of symptoms. Secondary outcomes were viral load, laboratory tests, serum biom"],"journal":["The European respiratory journal"],"pubmed_title":["Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial."],"pmcid":["PMC7758778"],"funding_grant_id":["403485/2020-7"],"pubmed_authors":["de Carvalho AF","Fernandes APSM","Paes NF","Luiz RR","Cordeiro AT","Maciel PVM","Proenca-Modena JL","Dos Santos IS","Pelosi P","Rocco PRM","Goncalves JMJ","Alves PA","Marques RE","Tierno PFGMM","Rocha RP","Lapa E Silva JR","Junior WF","Carbonieri MN","Melo-Junior MAC","De Oliveira LFG","Lima CC","Dos Santos EA","Cruz FF","Magri E","de Moraes NF","SARITA-2 investigators","Moura MA","Franchini KG","Silva PL","Trivella DBB"],"additional_accession":[]},"is_claimable":false,"name":"Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial.","description":"<h4>Background</h4>Nitazoxanide is widely available and exerts broad-spectrum antiviral activity <i>in vitro</i>. However, there is no evidence of its impact on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.<h4>Methods</h4>In a multicentre, randomised, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of coronavirus disease 2019 (COVID-19) symptoms (dry cough, fever and/or fatigue) were enrolled. After confirmation of SARS-CoV-2 infection using reverse transcriptase PCR on a nasopharyngeal swab, patients were randomised 1:1 to receive either nitazoxanide (500 mg) or placebo, three times daily, for 5 days. The primary outcome was complete resolution of symptoms. Secondary outcomes were viral load, laboratory tests, serum biom","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2026-06-06T22:57:09.934Z","creation":"2021-02-21T04:09:26Z"},"accession":"S-EPMC7758778","cross_references":{"pubmed":["33361100"],"doi":["10.1183/13993003.03725-2020"]}}